Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TACTIC: Colchicine in Acute Coronary Syndromes
NCT06215989Recruiting
- Sponsor
- Beijing An Zhen Hospital
- Start
- Sep 2024
- Primary completion
- Feb 2027
- Modality
- Nucleic Acid-Directed Small Molecules, Classical Binding Small Molecules, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Randomised, double-blind trial in acute coronary syndrome (ACS) comparing Colchicine Group with Placebo Group (2 arms). Primary endpoint: Major Adverse Cardiovascular Events at 1 year. Started Sep 2024; status: recruiting.
02
Drugs
colchicine
03
Conditions
acute coronary syndrome (ACS)
Beyond the preview
Go deeper on NCT06215989.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06215989.